|
  
- 现金
- 3700 元
- 精华
- 16
- 帖子
- 1790
- 注册时间
- 2002-12-9
- 最后登录
- 2021-4-14
|
1楼
发表于 2004-4-17 03:20
Durability of HBeAg Seroconversion After Adefovir Dipivoxil Treatment for Chronic Hepatitis B
The aim of the current study was to evaluate the durability of hepatitis B e antigen (HBeAg) seroconversion after adefovir dipivoxil (ADV) treatment in patients with CHB.
CHB patients with compensated liver function who had undergone HBeAg seroconversion defined as loss of HBeAg and appearance of antibodies against HBeAg (anti-HBe) confirmed on 2 consecutive visits at least 4 weeks apart, were enrolled in a long-term off treatment follow-up study.
Results
Seventy-six patients were enrolled; 63% male, 22% Caucasian, 76% Asian, median age 34 (range, 21?3) years at ADV discontinuation.
Median duration on ADV therapy was 80 weeks (range, 30?93) and patients have been off treatment for a median of 55 weeks postseroconversion (range, 5?25).
At time of ADV discontinuation, 87% (66 of 76) achieved undetectable HBV DNA as measured by Roche Amplicor MonitorTM PCR assay (LLQ < 1,000 copies/mL); 89% had normalized ALT (median 23 IU/L). Results at the last available observation are summarized below.
Last Available Observation (n=75)*
HBeAg-/Ab+ (seroconversion) 69 (92%)
HBeAg+/Ab-/HBV DNA ≥ 1000 copies/mL 4 (6%)
HBeAg-Ab-/HBV DNA ≥ 1000 copies/mL 1 (1%)
HBeAg-Ab-/HBV DNA < 1000 copies/mL 1 (1%)
Conclusions: HBeAg seroconversion achieved during ADV treatment is durable in greater than 90% of patients with a median follow-up of more than 1 year.
1National Cheng Kung University Hospital, Tainan, Taiwan; 2McGuire VAMC, Richmond, VA, USA; 3Huntington Memorial, Pasadena, CA, USA; 4Hopital Beaujon, Clichy, France; 5Chang- Gung Memorial Hospital, Taipei, Taiwan; 6Siriraj Hospital, Bangkok, Thailand; 7Gilead Sciences, Inc, Foster City, CA, USA.
04/16/04
Reference
T Chang and others (for the International Adefovir Dipivoxil 481 Study Group). Durability of HBeAg Seroconversion after Adefovir Dipivoxil Treatment for Chronic Hepatitis B. Abstract 424 (poster). 39th EASL. April 14-18, 2004. Berlin, Germany. |
|
